Literature DB >> 19653113

The factors that affect plasma homocysteine levels, pulse wave velocity and their relationship with cardiovascular disease indicators in peritoneal dialysis patients.

Sibel Ertek1, Ayse Nur Torun, Kenan Ates.   

Abstract

OBJECTIVE: The incidence of cardiovascular diseases (CVD) is high in end-stage renal disease (ESRD) population and hyperhomocysteinemia is an important CVD risk factor. The aims of this study are to asses the incidence of hyperhomocysteinemia and the factors that affect the homocysteine (Hcy) levels in peritoneal dialysis (PD) patients, and to analyze the relationships between Hcy levels and clinical and echocardiographic CVD, and the pulse wave velocity (PWV). STUDY
DESIGN: Sixty ESRD patients undergoing PD for at least 6 months were included in the study. Biochemical parameters, echocardiography, and PWV were analysed for every subject.
RESULTS: Mean Hcy level was 27.2 +/- 15.7 micromol/L and was high in 53 patients (88.3%). Fibrinogen, dialysate/plasma creatinine ratio and folic acid were found to be the independent predictors of Hcy level (P < 0.001; P < 0.01; P < 0.05, respectively). Patients with atherosclerosis had significantly higher plasma Hcy levels (P < 0.05). No significant relationship was found between plasma Hcy levels and echocardiographic findings and PWV.
CONCLUSION: Hyperhomocysteinemia incidence seems high among PD patients and despite significant relationship between fibrinogen and Hcy in our study, it is essential to evaluate the link between Hcy levels and inflammation. Folic acid replacement even in normal folic acid levels, enough elimination of volume and solutes may be beneficial to control Hcy levels, whereas PWV was found to be related with comorbidities and and dialysate kinetics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653113     DOI: 10.1007/s11255-009-9625-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  45 in total

1.  Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients.

Authors:  L A Bortolotto; M E Safar; E Billaud; C Lacroix; R Asmar; G M London; J Blacher
Journal:  Hypertension       Date:  1999-10       Impact factor: 10.190

Review 2.  Hyperhomocysteinemia in chronic renal disease.

Authors:  A G Bostom; B F Culleton
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

3.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

4.  Higher plasma homocysteine concentration is associated with more advanced systemic arterial stiffness and greater blood pressure response to stress in hypertensive patients.

Authors:  Jun Tayama; Masanori Munakata; Kaoru Yoshinaga; Takayoshi Toyota
Journal:  Hypertens Res       Date:  2006-06       Impact factor: 3.872

5.  The oxidant stress of hyperhomocyst(e)inemia.

Authors:  J Loscalzo
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

6.  Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients.

Authors:  A Vychytil; M Födinger; M Papagiannopoulos; G Wölfl; W H Hörl; G Sunder-Plassmann
Journal:  Kidney Int       Date:  1999-05       Impact factor: 10.612

7.  Plasma levels of homocysteine in patients with white-coat hypertension.

Authors:  E Coban; M Ozdoğan; C Ermiş
Journal:  Int J Clin Pract       Date:  2004-11       Impact factor: 2.503

8.  Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives.

Authors:  Maurizio Cesari; Mario Zanchetta; Alberto Burlina; Luigi Pedon; Giuseppe Maiolino; Daniele Sticchi; Achille C Pessina; Gian Paolo Rossi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-11-04       Impact factor: 8.311

9.  The associations between smoking, physical activity, dietary habits and plasma homocysteine levels in cardiovascular disease-free people: the 'ATTICA' study.

Authors:  Christina Chrysohoou; Demosthenes B Panagiotakos; Christos Pitsavos; Akis Zeimbekis; Antonis Zampelas; Lambros Papademetriou; Constantina Masoura; Christodoulos Stefanadis
Journal:  Vasc Med       Date:  2004-05       Impact factor: 3.239

10.  Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.

Authors:  Karsten Sydow; Burkhard Hornig; Naoshi Arakawa; Stefanie M Bode-Böger; Dimitrios Tsikas; Thomas Münzel; Rainer H Böger
Journal:  Vasc Med       Date:  2004-05       Impact factor: 3.239

View more
  2 in total

1.  Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients.

Authors:  Sena Memnune Ulu; Seref Yuksel; Atila Altuntaş; Emre Kacar; Ahmet Ahsen; Abdullah Altug; Sefa Celik; M Tugrul Sezer
Journal:  Int Urol Nephrol       Date:  2014-06-08       Impact factor: 2.370

2.  Comparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patients.

Authors:  Ozlem Harmankaya; Nilgul Akalin; Hatice Akay; Yildiz Okuturlar; Kayhan Erturk; Hakan Kaptanogullari; Hakan Kocoglu
Journal:  Clinics (Sao Paulo)       Date:  2015-09       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.